###### Strengths and limitations of this study

-   There are few published studies demonstrating the beneficial effects of weight loss or exercise programmes on cardiac remodelling and function in people with type 2 diabetes (T2D).

-   The Diabetes Interventional Assessment of Slimming or Training tO Lessen Inconspicuous Cardiovascular Dysfunction study will comprehensively describe changes in cardiac structure and function in younger obese people with T2D treated with either a low-energy meal replacement diet or exercise programme.

-   This is a proof-of-efficacy study, and therefore, effects on clinical outcomes is not planned with a short duration of follow-up.

-   Only patients who are able to exercise and willing to undertake the meal replacement plan are eligible, and we have limited our inclusion to younger adults (\<65 years) with a maximum duration of diabetes of 12 years, so the results will not necessarily be generalisable to all people with T2D.

-   Recruitment to the study ended in August 2018.

Background {#s1}
==========

Recent estimates suggest there are currently 425 million people with type 2 diabetes mellitus (T2D) globally.[@R1] The dramatic rise in the levels of obesity and sedentary lifestyles in younger age groups has resulted in up to a 10-fold increase in the prevalence of T2D in younger adults.[@R2] Whereas T2D was once a rarity in young people, increasingly we are seeing the condition diagnosed in children, adolescents and adults under the age of 30 years.[@R3] The onset of T2D in younger people represents an extreme phenotype that magnifies the disease profile observed in older adults. This is of clinical significance and represents an important public health issue.

The most deleterious consequence of developing T2D is a substantially elevated risk of cardiovascular disease (CVD), a feature that is magnified in younger adults. For example, the 20-year mortality rate in younger adults with T2D is as high as 11%, the majority from CVD.[@R5] Furthermore, 48% of young adults with obesity at 22 years of age experience some form of CVD or early mortality with a life expectancy of 55 years.[@R6] This is a rapidly emerging clinical pattern, where the mechanisms driving the high disease burden in younger adults with T2D, and potential therapeutic strategies, have not been fully elucidated.

While the risk of developing coronary artery disease and stroke are well recognised, the association of diabetes with heart failure (HF) has received less attention.[@R7] Diabetes is an independent risk factor for the development of HF.[@R8] In the 2015--2016 UK National Diabetes Audit, there were 115 695 emergency admissions for patients with diabetes and HF (32.5% of all HF admissions) despite people with diabetes representing only 8% of the population. Importantly, as many as half of all patients in the community with HF are asymptomatic.[@R11] There is a high prevalence of people with diabetes with both common forms of HF: reduced systolic left ventricular (LV) function and HF with preserved ejection fraction (which represents up to 50% of cases in the community).[@R12]

Diabetic cardiomyopathy: the precursor to clinical HF {#s1a}
-----------------------------------------------------

Diabetic cardiomyopathy is defined as myocardial disease in patients with diabetes, not attributable to hypertension, coronary artery disease or other cardiac disease.[@R13] The pathophysiology of diabetic cardiomyopathy is complex, involving metabolic, vascular, inflammatory, epigenetic and neuroendocrine mechanisms. Diastolic (relaxation/filling) dysfunction and concentric LV remodelling typify most cases, with a prevalence of up to 75% in adults with T2D.[@R14] Multiple parameters have been associated with diastolic dysfunction including glycated haemoglobin (HbA1c) level,[@R17] age,[@R18] aortic stiffness,[@R19] duration of diabetes,[@R19] microvascular dysfunction[@R20] and myocardial triglyceride content.[@R21]

Pilot data: cardiovascular dysfunction in younger adults with T2D {#s1b}
-----------------------------------------------------------------

A pilot Medical Research Council (MRC)-funded study investigating the biochemical and cardiac abnormalities associated with T2D in younger adults (18--40 years) was conducted by our group.[@R19] Twenty young adults with diagnosed T2D, 20 age-matched metabolically healthy obese and 10 lean controls were recruited. Cardiac structure and function were assessed by tagged cardiac MRI (CMRI) and myocardial perfusion and scarring were assessed with contrast-enhanced CMRI. There were elevated inflammatory markers (high sensitivity C-reactive protein (hsCRP), interleukin-6 and 10 and tumour necrosis factor-alpha), reduced adiponectin and a strong trend for concentric remodelling (increased LV mass/volume) in both the T2D and obese controls versus the lean controls. The most striking finding was evidence of greater diastolic dysfunction in T2D compared with both the obese and lean controls.[@R19] Specifically, peak early diastolic strain rate (PEDSR) had an average value of $\begin{array}{l}
{1.3\frac{1}{s}} \\
\end{array}$ in the patients with T2D, which was 20% lower than the obese controls and 30% lower compared with the lean controls. There was also a strong trend towards reduced systolic strain in T2D (−21%) compared with both control groups (−23%, p=0.08), which suggests these patients may be at risk of incipient systolic dysfunction and are indeed already at the threshold of early diabetic cardiomyopathy.

These results were consistent with a larger echocardiographic study in adolescents with diabetes compared with lean and obese controls.[@R24] There is a growing body of evidence that preclinical diastolic dysfunction is already manifest in younger adults with T2D, despite their relatively young age and short duration of T2D. This is of high clinical relevance and suggests that the high risk of CVD observed in T2D may be linked to diastolic dysfunction, predisposing these patients to HF, in advance of overt systolic compromise.[@R14] Therefore, therapeutic strategies that target both glycaemic control and diastolic cardiac function are highly desirable in younger adults with T2D to prevent the development of HF.

Interventions to reverse diastolic dysfunction in T2D {#s1c}
-----------------------------------------------------

Proof that T2D is a reversible condition has been firmly established in patients undergoing bariatric surgery[@R25] and more recently with intensive primary care-led weight management in the Diabetes Remission Clinical Trial (DiRECT) trial.[@R27] The extent of weight loss is strongly linked to reversal of T2D (with a diabetes remission rate of 7% with weight loss \<5 kg vs 86% with weight loss ≥15 kg),[@R27] as is good glycaemic control before surgery.[@R26] Insulin use, diabetes duration and high HbA1c levels are associated with reduced likelihood of reversal.[@R26] These studies, however, have not assessed changes in cardiovascular function.

### Low and very low energy diets (VLEDs) {#s1c1}

The phenotypic characteristics of T2D (excess body weight, ectopic fat deposition and insulin resistance) are largely normalised through VLEDs (typically \<800 kcal/day) via a meal replacement approach. Many of the metabolic responses mimic adaptions following bariatric surgery.[@R28] A proof-of-concept study showed that just 8 weeks of 510kcal/day diet via this approach resulted in normalisation of fasting glucose, hepatic glucose production and hepatic triglyceride content with substantial improvements in glucose disposal rates.[@R29] In a larger (n=298) recent trial of a low-energy total diet replacement programme (825--853 kcal/day over 3--5 months) versus guideline-driven best practice, diabetes remission was achieved in almost half (46%) of those who received the diet (mean weight loss 10 kg) compared with only 4% in the comparator group (mean weight loss 1 kg).[@R27] Many of these improvements are seen within 1 week. The majority of T2D individuals are also found to lose 50% of excess body weight within 8--12 weeks of VLED.[@R29] In a self-reported study of dietary induced weight loss, diabetes reversal was positively associated with the magnitude of weight loss and inversely with diabetes duration (being lowest in those with diabetes \>8 years).[@R31]

In obese subjects without T2D, sustained weight loss, either with diet or after surgery, has resulted in favourable reductions in cardiovascular MRI (CMRI) measured LV mass, volumes, arterial stiffness and diastolic function.[@R32] Improved diastolic function following weight loss in obesity has been associated with improved energetics[@R33] and with reduced myocardial triglyceride content.[@R34] In patients with insulin-treated T2D, a 471 kcal/day VLED has also been shown to reduce myocardial steatosis (0.88%±0.12% to 0.64±0.14%, p=0.02) in a small (n=12) single-group study and was associated with improved diastolic filling on CMR.[@R35] Interestingly, a brief report from the same group suggests that in the first few days after commencing a VLED there may actually be an increase in steatosis and reduced diastolic filling.[@R36]

There is a wide range of research incorporating the use of LED/VLED; however, the definition in practice is somewhat blurred, with VLED often much lower than 800 kcal/day. It is recognised that weight loss results from LED around 800 kcal/day are similar to those with lower energy intakes but with fewer adverse effects including limited loss of lean mass.[@R37] For this study, we therefore chose a diet based on an intake of ≈810 kcal/day (Cambridge Weight Plan).

### Exercise programmes {#s1c2}

Physical activity has consistently been associated with a reduced risk of T2D and a reduced risk of premature mortality and CVD mortality in those with diagnosed T2D.[@R38] Interventional studies have demonstrated a strong causal link between exercise training and glycaemic control in those with T2D. Indeed, exercise training has consistently been found to lower HbA1c by 0.6%--0.7%, with greater effects seen with higher volumes of exercise.[@R40] Importantly, these substantial benefits are maintained when exercise training does not result in weight loss.[@R40] This is consistent with experimental studies that have elucidated key insulin-dependent and insulin-independent pathways linking physical activity to improved glucose regulation that do not act through adiposity.[@R42] Therefore, physical activity is an effective therapy for promoting metabolic health and glucose regulation independent of body weight. While the benefits of exercise training on glycaemic control are well established, the effects on diastolic function are less well known, primarily due to insufficient data, differences in measurement and poor study design. However, encouraging data are starting to emerge in those with obesity. For example, an 8-week exercise training programme in obese men improved diastolic function to levels seen in lean controls, despite no weight loss.[@R44] Similarly, just 4 weeks of exercise training has been shown to improve diastolic function in those with HF with similar improvements also observed in a matched cohort without HF.[@R45]

Only two studies that we are aware of have been conducted specifically in people with T2D assessing the effects of exercise training on diastolic function. A small pilot study found improvements in diastolic function following 3 months of aerobic exercise training in those with T2D (although tissue Doppler imaging was not performed, and the randomised groups were not well matched),[@R46] while another study found no overall effect.[@R47] However, in the latter study, a post hoc analysis revealed that change in moderate-intensity physical activity was significantly associated with change in myocardial strain rate, although it is unclear whether this was systolic, diastolic or both.[@R47] This mirrors the wider evidence where light-to-moderate aerobic exercise training has repeatedly been demonstrated to improve diastolic function across a number of groups.[@R44] The effectiveness of vigorous-intensity exercise or combined aerobic and resistance training is less well established, with at least one study showing the latter approach is not effective.[@R48] Given this evidence base, it is important the efficacy of aerobic exercise training is investigated further, including in younger adults with T2D.

Aims {#s1d}
----

The primary aim of the study is to determine if diastolic function can be improved by either a meal replacement low energy diet plan (MRP) or a supervised exercise programme, compared with guideline-directed care. Key secondary aims are to assess the effects of the interventions on glycaemic control and insulin resistance, exercise capacity, blood pressure, changes in body composition and association of favourable cardiac remodelling with improvements in weight loss, exercise capacity and glycometabolic control. The primary hypothesis is that an MRP and/or exercise will improve diastolic function when compared with standard care alone.

Methods and analysis {#s2}
====================

Study design {#s2a}
------------

This is a single-centre study, which will comprise a baseline and follow-up analysis of a three-arm 12-week prospective, randomised, open-label, blinded end point trial of a low-energy MRP and an exercise programme compared with standard care in young adults with T2D.

Study population {#s2b}
----------------

Potential participants will be identified from both primary and secondary care in Leicester, Leicestershire and Rutland using electronic databases and with support from the National Institute for Health Research East Midlands Local Clinical Research Network. At-risk groups, such as slimming clubs/weight watchers, will also be contacted within the local community. All patients meeting the inclusion and exclusion criteria ([table 1](#T1){ref-type="table"}) will proceed to the baseline visit and the study. We describe our age range as 'younger' and not specifically as 'young' as in developed countries, diabetes prevalence peaks between the ages of 75 years and 79 years.[@R49] In this study, the inclusion of people with T2D \<65 years therefore classifies the cohort as younger relative to the general UK population of people with T2D. A Consolidated Standards of Reporting Trials (CONSORT) diagram will be produced, which will include the number of patients: approached, consenting, meeting eligibility criteria, randomised and completing each phase of the study.

###### 

Inclusion and exclusion criteria

  Inclusion criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Exclusion criteria
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Capacity to provide informed consent before any trial-related activities.Established T2D (≥3 months).HbA1c ≤9% if on triple therapy or ≤10% on diet and exercise or monotherapy or dual therapy.Current glucose-lowering therapy either mono, dual or triple of any combination of metformin, sulphonylurea, DPP-IV inhibitor, GLP-1 therapy or an SGLT2i±diet and exercise.Poorly managed diet controlled diabetes (with HbA1c \>6.5%, not currently taking any glucose-lowering therapy, meeting BMI inclusion range).BMI \>30 kg/m^2^ or \>27 kg/m^2^ (South Asian).Diagnosis of T2D before the age of 60 years of age.Age ≥18 and ≤65 years.   Diabetes duration \>12 years.Currently taking more than three glucose-lowering therapies.Weight loss of \>5 kg in the preceding 6 months.Stage 4 or 5 chronic kidney disease (eGFR \<30 mL/min/1.73 m^2^).Current therapy with insulin, thiazolidinediones, steroids or atypical antipsychotic medication.Untreated thyroid disease.Known macrovascular disease including coronary artery disease, stroke/TIA or peripheral vascular disease.Presence of arrhythmia (including atrial fibrillation, atrial flutter or second or third degree atrioventricular block).Known heart failure or other clinically relevant heart disease.Inability to exercise or undertake a MRP.Absolute contraindication to CMRI.Cardiovascular symptoms (angina and limiting dyspnoea during normal physical activity).Inflammatory condition, for example, connective tissue disorder and rheumatoid arthritis.

BMI, body mass index; CMRI, cardiovascular MRI; DPP-IV, dipeptidyl peptidase-IV inhibitor; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide 1; MRP, meal replacement plan; SGLT2i, sodium glucose cotransporter 2 inhibitor; T2D, type 2 diabetes; TIA, transient ischaemic attack.

Study visits {#s2c}
------------

An outline of study visits and measures taken is shown in [figure 1](#F1){ref-type="fig"}. Participants are offered £50 compensation for each of the three assessment visits completed (baseline, 4-week and 12-week visits).

![Study overview. CMR, cardiac MRI; CPET, cardiopulmonary exercise testing; MRP, meal replacement plan MRP.](bmjopen-2018-023207f01){#F1}

### Baseline visit and randomisation {#s2c1}

A study clinician will check eligibility of the potential participant and obtain written informed consent. Baseline data including patients' demographics, medical history and anthropometric measures (height, weight, body mass index, blood pressure and waist and hip measurements) will be collected. Total fat mass and fat free mass will be assessed by a dual-energy X-ray absorptiometry (DEXA) scan (Lunar iDEXA, General Electric Healthcare, Bedford, UK). Habitual physical activity and sedentary time will be assessed using objective (ActiGraph GT3X+ accelerometer, USA) and subjective (physical activity questionnaires) measures. A fasting blood sample will also be taken to check a range of measures including a biochemical profile for diabetes control, liver and kidney function and lipid profile, together with other measures of endocrine function (eg, fasting insulin, C-peptide and thyroid function tests) and inflammation. Insulin resistance will be estimated using the homeostatic model assessment-insulin resistance method[@R50] and the triglyceride/high-density lipoprotein (HDL) ratio.[@R51] Additional blood samples will be collected for the storage of plasma and serum for future metabolomic and proteomic investigation.

Participants will undergo comprehensive CMRI scanning and transthoracic echocardiography performed at baseline as outlined below. They will then undergo a maximum symptom-limited incremental exercise test on a stationary electromagnetically braked cycle ergometer (eBike, General Electric Healthcare, Bedford, UK) with expired gas analysis (Ganshorn PowerCube, General Electric Healthcare, Bedford, UK) to determine peak oxygen consumption (oxygen consumption (VO~2~)), the gold standard assessment of cardiovascular fitness.[@R52]

### Randomisation {#s2c2}

Participants will undergo randomisation at the baseline visit, using an independent online computerised randomisation system (Sealed Envelope). Randomisation will be stratified by sex, given different LV remodelling processes in men and women,[@R53] and by baseline glucose-lowering therapy (any glucagon-like peptide-1, dipeptidyl peptidase-IV or sodium glucose cotransporter 2 inhibitor vs none of these).

### Study interventions {#s2c3}

Recruited participants will be randomised to one of three groups: (1) standard of care as per National Institute for Health and Care Excellence guidance[@R54] including lifestyle advice, (2) MRP or (3) supervised exercise training.

1. The standard care group will be provided with standard lifestyle advice according to National Institute for Health and Care Excellence guidance,[@R55] delivered in a single health coaching interview at week 0. This lifestyle advice will be reinforced at the week 12 assessment.

2. The MRP group will receive a low-energy MRP diet containing an average of ≈810 kcal/day (30% protein, 50% carbohydrate, 20% fat) (Cambridge Weight Plan). This diet plan complies with all current guidance and government legislation (European Food Safety Authority) for macronutrient and micronutrient content and quality.[@R56] Participants randomised to the MRP group will be asked to discontinue all glucose-lowering therapies following randomisation to avoid hypoglycaemia. Antihypertensive drugs will be stopped on the day of low-energy diet commencement, as a safety measure because blood pressure is likely to fall substantially (mean drop in systolic blood pressure \~20 mm Hg) on the diet.[@R35] Any alterations to medication will ultimately be made at the discretion of the study clinician(s). The clinical team will include specialists in CVD and diabetes medicine to oversee alterations in antihypertensive and glucose-lowering therapy. Blood pressure and glucose will be monitored throughout the study at the clinical review sessions (see below).

The MRP will be undertaken alongside health behaviour coaching and relapse prevention through weekly contact, where possible, with a qualified dietician or equivalent. Participants will be asked to maintain their usual daily activities and not initiate any additional physical activity for the duration of the study. Those participants in the MRP arm who do not achieve a loss of \>2% body weight at week 1 and 4% at week 3 will be considered non-compliant and excluded from the study. Investigator discretion will be used when considering non-compliance in the event of borderline values. The diet will be stopped, and a maintenance diet reintroduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first. The maintenance diet will be individualised and agreed with the participant, based on their estimated total energy expenditure at that point. The self-reported intake at week 12 will be recorded and comparisons made between arms for macronutrient and energy intake.

3. The exercise group will attend supervised sessions at the Leicester Biomedical Research Centre. The exercise programme will be undertaken thrice weekly, progressing to 50 min per session of moderate intensity aerobic exercise, in line with prevailing guidelines (150 min per week). Each exercise session will consist of a warm-up, stimulus and cool-down phase. Static stretching will be undertaken at the end of each session. The stimulus phase will include walking and/or lower extremity cycling. The duration of exercise in each training mode will also be increased gradually to achieve the 50 min target. An initial assessment of cardiorespiratory fitness will be performed, and exercise intensity titrated using the value from the baseline peak VO~2~ assessment. Objective (heart rate monitoring) and subjective (Borg Rate of Perceived Exertion Scale, graded from 6 to 20) measures will be used to measure responses to the exercise sessions with exercise intensity adjusted progressively to take account of increasing fitness levels throughout the intervention period as follows:

Weeks 1 and 2: 15 min at \~50% peak VO~2~.

Week 3: 25 min at \~60% peak VO~2~.

Week 4: 30 min at \~60% peak VO~2~.

Week 5: 35 min at \~60% peak VO~2~.

Week 6: 40 min at \~60% peak VO~2~.

Week 7: 45 min at \~60% peak VO~2~.

Weeks 8--12: 50 min at \~60% peak VO~2~.

Although weight loss may occur in the exercise group, this is not the main aim of the intervention, which is to assess whether diastolic function improves independent of weight loss. Compliance will be assessed by attendance at the supervised sessions. Patients in the exercise arm who attend less than two-thirds of the supervised sessions in the first 4 weeks and then throughout the remainder of the study period will be excluded. Investigator discretion may be used in cases where compliance is borderline.

Participants will be asked to maintain their usual dietary intake, and a self-reported food diary will be applied before and after the intervention to estimate intake. Participants in the exercise arm will have their medication reviewed by the study clinician at baseline. Those with an HbA1c ≤8% who are currently taking a sulphonylurea will initially have the dose reduced by 50% 72 hours prior to the first exercise session. Their regimes will be continued to be down-titrated starting with the sulphonylurea and then moving, where applicable, onto their current sodium glucose cotransporter-2 inhibitor or dipeptidyl peptidase-IV inhibitor or glucagon-like peptide-1 therapies according to glycaemic control. The latter therapies will be titrated down last given their relative low risk of hypoglycaemic events. For those participants with an HbA1c ≤8% who are not taking a sulphonylurea, the study clinician will down-titrate glucose-lowering therapy on an individual basis, taking into account the class and combination of therapies prescribed. All other medication will be maintained unless the study clinician deems alterations are necessary for a patient's best interest. Alterations in medication will be supervised by clinicians specialised in diabetes medicine.

### Subsequent clinical reviews {#s2c4}

All participants will have an initial clinical review postrandomisation at the time of their health coaching. In order to ensure their continued safety, each participant in the MRP or exercise arm will be invited for frequent clinical reviews. They will attend six reviews after randomisation in total (weeks 1, 2, 4, 6, 8 and 12), as well as receiving a telephone consultation at weeks 3 and 10. At these clinical reviews their blood pressure, fasting glucose (weeks 1, 2 and 4 for MRP arm) and weight will be measured. This is to inform: (A) any additional alterations to medication that need to be made and (B) compliance to the MRP and exercise programme as appropriate.

### Optional 4-week visit {#s2c5}

The 4-week assessment is optional and will only be conducted on a subset of participants who provide additional consent. Measures taken during the baseline visit will be repeated to ascertain whether there are early alterations to outcome measures in participants randomised to the study interventions.

### Twelve-week final data collection visit {#s2c6}

All measures and tests undertaken at the baseline visit will be repeated at the 12-week final data collection visit. Participants will undergo one further clinical review (see above) following the 12-week data collection visit, which will be the final visit and the end of the study. Medications will be reviewed, and any medication reintroduced will be tailored to the individual based on previous and current HbA1c and blood pressures. This review will be undertaken by an experienced study clinician and the outcome communicated to the patient's usual physician and general practitioner.

### Blood glucose monitoring {#s2c7}

Participants in both intervention arms (MRP and exercise) will be provided with blood glucose monitoring equipment to capture seven-point glucose profiles across key time-points during the study (prior to initial consultation week 0, prior to the 4-week visit and prior to 12-week visit), which will be recorded in a blood glucose monitoring diary and/or via direct download of the blood glucose metre data at the end of the study where possible. It will also allow them to self-monitor their glucose levels through the study and capture any hypoglycaemic events to guide medication adjustments accordingly if required. Additionally, hyperglycaemia will be assessed, and medication adjusted if necessary after review of compliance to intervention. These will be self-reported by the participant in the blood glucose monitoring diary.

Magnetic resonance imaging {#s2d}
--------------------------

Reproducibility of PEDSR appears to be better at 1.5T than at 3T, and therefore, 1.5T is our preferred field strength for CMR assessment of diastolic function.[@R57] Myocardial triglyceride on the other hand is measured using magnetic resonance spectroscopy, a technique generally considered to be best performed at 3T, due to the higher signal to noise ratio compared with 1.5T.[@R58] We will therefore perform magnetic resonance spectroscopy on a 3T scanner (Skyra, Siemens, Erlangen), with all other MRI data being collected on a 1.5T scanner (Aera, Siemens, Erlangen).

The MRI protocol is outlined in [figure 2](#F2){ref-type="fig"} and is similar to that described previously.[@R59] An exception to this is that myocardial tissue tagging and T1 mapping have been omitted. Myocardial tissue tagging requires the acquisition of additional images with long breath hold duration and is time consuming to analyse. Alternatives include phase velocity mapping, displacement encoding with simulated echoes and strain-encoded images, all of which require the acquisition of additional sequences and/or involve lengthy postprocessing times.[@R60] Instead, we will use tissue tracking of balanced steady-state free precession LV cine images, which has emerged as a reliable alternative technique for the assessment of strain and diastolic strain rate[@R57] with good test-test reproducibility for PEDSR in our lab.[@R56]

![1.5 Tesla CMR protocol for covering thoracic and abdominal subcutaneous and visceral fat (Dixon) function (cine), arterial stiffness and late gadolinium enhancement for focal fibrosis. CMR, cardiac MRI; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle; SAO, sagittal oblique.](bmjopen-2018-023207f02){#F2}

Briefly, after localisers, Dixon gradient echo pulse sequences covering the thorax and abdomen will be acquired for thoracic and abdominal subcutaneous and visceral fat. Liver triglyceride content will also be assessed by HepaFat-Scan, which has been validated against stereological analysis of liver biopsy sections for measurement of liver fat fraction.[@R63] Steady-state free precession cine images will be acquired in four-chamber, three-chamber and two-chamber views. Perfusion images will be acquired after pharmacological vasodilation with adenosine (140 µg/kg/min, for 2--3 min) until a haemodynamic response is achieved (a drop in systolic blood pressure of 10 mm Hg and/or rise in heart rate of 10 bpm). During peak stress, a gadolinium-based contrast agent (Gadoterate meglumine, Dotarem, Guerbet LLC, France) will be injected (0.04 mmol/kg), followed by a 20 mL bolus of normal saline, at a rate of 5 mL/s, and perfusion images will be acquired using a saturation recovery gradient echo pulse sequence for three slices (basal, mid and apical). Rest imaging will be performed approximately 10 min after stress imaging with a further 0.04 mmol/kg of contrast. In the intervening time, a stack of short-axis slices will be obtained using cine images covering the entire LV. A further 0.07 mmol/kg top-up of contrast will be administered to bring the total contrast dose to 0.15 mmol/kg. Aortic cine images will be acquired in a plane perpendicular to the thoracic aorta at the level of the pulmonary artery bifurcation. Through-plane phase contrast sequences perpendicular to the ascending and descending aorta at the level of the pulmonary bifurcation will be captured for pulse wave flow analysis. To determine the aortic arch segment length between which aortic pulse wave velocity is calculated, sagittal oblique aortic cine images will be acquired. At least 10 min after top-up contrast administration, late gadolinium enhancement images will be obtained with an inversion-recovery prepared, segmented gradient echo sequence.

CMRI analysis {#s2e}
-------------

Scans will be anonymised and sent to a standalone workstation for blinded analysis as previously described.[@R19] Briefly systolic strain and longitudinal PEDSR will be quantified from cine images using tissue tracking. LV volumes, mass and function will be calculated using commercially available software (cmr42, Circle Cardiovascular Imaging, Calgary, Canada). Myocardial strain will be measured using both Image Arena Feature Tracking (TomTec Imaging Systems, Unterschleissheim, Germany) and cmr42 Tissue Tracking (Circle Cardiovascular Imaging). Interobserver and intraobserver variability will be calculated on at least 10 random datasets by two experiences observers and results reported. Test--retest reproducibility will be assessed for the primary endpoint in 10 subjects and the analysis technique that has the best reproducibility will be used for the final analysis, and if they have similar reproducibility, we will use tissue tracking since this can be generated using the contours drawn for LV mass analysis. The epicardium and endocardium will be contoured on the perfusion images, along with a region of interest in the LV blood pool to generate signal intensity curves. Myocardial perfusion reserve will be calculated using Fermi-constrained deconvolution as previously described.[@R19] Late gadolinium enhancement will be assessed qualitatively as absent or present and quantified by a thresholding technique \>5 SDS above remote normal myocardium.[@R64]

Transthoracic echocardiography {#s2f}
------------------------------

Comprehensive transthoracic echocardiography will be performed according to British Society of Echocardiography guidelines.[@R65] Each participant will have assessment for: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function. Given the difficulties in grading diastolic dysfunction in mild and moderate disease,[@R66] the primary focus on echocardiography will be on E/e′, a non-invasive surrogate of LV filling pressure.[@R67] Mitral annular velocities (e′) will also be reported to account for the possibility that enlarged left atrial volumes may result in a decreased E wave velocity and apparent reduction of E/e′ in people with diabetes.[@R68]

Study outcomes {#s2g}
--------------

### Primary outcome {#s2g1}

The primary outcome measure is change in circumferential PEDSR, measured by CMR from baseline to 12 weeks. Other measures of cardiac structure and function assessed in the study are shown in [box 1](#B1){ref-type="boxed-text"}.Box 1Key imaging outcome measuresPrimary outcome measuresChange in circumferential PEDSR measured from baseline to 12 weeks.Secondary outcome measuresLongitudinal PEDSR.Standard assessments of structure and function (eg, LV mass, end-diastolic/systolic volumes, mass/volume and ejection fraction).Left atrial volumes.Myocardial systolic strain/strain rates (circumferential and longitudinal).Arterial stiffness (mean ascending and descending aortic distensibility and pulse-wave velocity).Global myocardial perfusion reserve as a marker of microvascular function.Myocardial and liver triglyceride content.Echocardiographic mitral inflow velocity (E), myocardial relaxation (E′) and E/E′, a non-invasive marker of LV filling pressure. Diastolic dysfunction will be graded.[^1]

Secondary outcomes {#s2h}
------------------

### Anthropometric variables {#s2h1}

Body weight, height, hip and waist circumference will be measured to the nearest 0.1 kg, 1 cm, 1 cm and 1 cm, respectively. Waist circumference will be measured using a soft tape with the participant standing, feet together, at the level of the umbilicus. Hip circumference will be measured at the level of the greater trochanters. Brachial blood pressure will be obtained from the seated participant's dominant arm. Three measurements will be taken and an average of the last two measurements will be used. Ethnicity, smoking status, medical history and medications history will be obtained by self-report.

### Biochemical variables {#s2h2}

Standard biochemical outcomes will be assessed by venous blood sampling. These will include fasting glucose and HbA1c, lipid profile (fasting triglycerides, HDL, low-density lipoprotein and total cholesterol), urea and electrolytes (sodium, potassium, urea and creatinine) and liver function tests (albumin, total bilirubin, alkaline phosphatase and alanine transaminase). Postmeal increase of glucose and absolute values of postmeal glucose will be assessed from the seven-point glucose profile.

### Cardiovascular fitness {#s2h3}

Participants will undergo a maximum incremental exercise test on a stationary bicycle (electromagnetically braked cycle ergometer) with expired gas analysis to determine peak VO~2~. The exercise test will begin with a 3 min warm-up phase and end with a 3 min cool-down phase. One-minute workload increments will be based on patient age, gender, height and weight.[@R52] The test will be physician supervised, and blood pressure will be recording at 2 min intervals. Indications for medical termination will be as previously described.[@R69] A quality control cardiopulmonary exercise test is undertaken every 6 weeks using a biological control in our unit. The coefficient of variation for VO~2~ (L/min) during steady state at workloads of 75, 100, 125 and 150 watts is consistently \<8%.

### Recent Physical Activity Questionnaire {#s2h4}

Self-reported physical activity will be measured using the Recent Physical Activity Questionnaire as previously described.[@R70] This assesses physical activity across four domains (domestic, recreational, occupational and commuting) over the previous month. The Recent Physical Activity Questionnaire has been shown to be a reliable and valid tool for measuring physical activity.[@R71]

### Accelerometer {#s2h5}

Participants will be asked to wear the accelerometer on a waistband (in the right anterior axillary line) during waking hours for seven consecutive days. A log sheet is provided for participants to record each day that they wear the accelerometer and document when the accelerometer was removed at night, time they went to sleep, time they woke up and time the accelerometer was reattached. Participants will return the accelerometer and log sheet via prepaid envelope at the end of 7 days of wear. A minimum of 3 days valid wear will be required to count as a valid recording. Raw acceleration data are captured and stored at 100 Hz. Data processing will be undertaken on commercially available analysis software.

### Dual-energy X-ray absorptiometry {#s2h6}

Each participant will undergo a DEXA scan using a total-body scanner. DEXA uses a technology by which the radiation at two energies is used to determine components of the attenuating tissue, either bone and soft tissue or lean soft tissue and fat. DEXA has been validated as a measure of body fat in obese and normal weight individuals[@R72] and as such is considered to be one of the gold standard measurements for determining body composition.

Estimates of total and regional fat mass and fat free mass will be automatically derived using the iDEXA encore software. Areas of particular interest include the appendages and trunk (encompassing android and gynoid regions). Daily quality assurance and quality controls will be carried out during the study period according to standard procedures supplied by the manufacturer. The volunteers will be scanned using standard imaging and positioning protocols.

Statistical analyses {#s2i}
--------------------

### Sample sizes {#s2i1}

The power calculation is based on the previously mentioned pilot study from our group.[@R19] The patients with T2D had a circumferential PEDSR of $\begin{array}{l}
{1.5\frac{1}{s}} \\
\end{array}$ with SD of $\begin{array}{l}
{0.2\frac{1}{s}} \\
\end{array}$. Based on this, 30 patients per group will have 80% power to detect a between group difference in PEDSR of $\begin{array}{l}
{0.2\frac{1}{s}} \\
\end{array}$ assuming alpha=0.025 (to allow for two primary comparisons, ie, MRP vs standard care and exercise vs standard care) and a maximum 30% dropout.[@R29] Such an improvement would result in a strain rate $\begin{array}{l}
{(1.7\frac{1}{s})} \\
\end{array}$ similar to that seen in the obese controls $\begin{array}{l}
{(1.8\frac{1}{s})} \\
\end{array}$ but still lower than the lean controls $\begin{array}{l}
{(2.0\frac{1}{s})} \\
\end{array}$.

### Statistical methods and analyses {#s2i2}

The aim of these analyses is to compare the change in primary outcome (PEDSR) at 12 weeks between the MRP and standard care arms, and between the exercise and standard care arms. The primary analysis will be a complete case analysis as this is a proof of principle study where we are primarily interested in the size of the treatment effect, rather than the practicability of the intervention. A CONSORT diagram will be produced. At baseline and each follow-up, descriptive variables and changes in outcomes will be summarised by arm using mean (SD) for normally distributed continuous variables, median (IQR) for non-normally distributed continuous variables and count (percentage) for categorical variables. Each intervention will be compared with the control group (ie, MRP vs standard care and exercise vs standard care) using linear regression adjusted for stratification factors and baseline values. The exercise and MRP arms will be compared as a secondary analysis. If necessary, the outcome variable will be appropriately transformed so that the assumptions of the linear regression model are held. Intention-to-treat analyses will be performed as sensitivity analyses using multiple imputation or another appropriate approach to impute missing data.

### Patient and public involvement (PPI) {#s2i3}

The University of Leicester and the Leicester NIHR Biomedical Research Centre have very active PPI groups in both diabetes and cardiovascular sciences. The study outline was presented to our PPI groups for feedback prior to designing the study protocol. In addition, PPI focus groups were held about the study design and conduct before the protocol was finalised. In particular, the PPI groups assessed the burden of the exercise and acceptability of the MRP arms on study participants to ensure appropriate support was available to help compliance with these interventions. Furthermore, the trial steering committee (see below) has at least two lay members for study oversight. All study participants and members of the public will be invited to return for a lecture disseminating the study's key findings on completion.

### Trial oversight and governance {#s2i4}

The study sponsor is the University of Leicester and is managed by the Leicester Clinical Trials Unit (CTU) and is overseen by the trial steering committee composed of an independent chair and a group of experts. The independent chair of the trial steering committee is Professor Roy Taylor, professor of medicine and metabolism and director of the Magnetic Resonance Centre, Newcastle University. This study is registered on <http://www.clinicaltrials.gov> and monitored by the University of Leicester. Data completeness and quality is reviewed by the Leicester CTU. The quality of 10 randomly selected baseline MRI datasets was assessed by an independent laboratory (Professor Sven Plein, Leeds, UK) and all images were graded as excellent or good.

Given the open design of the study, it was determined that a data monitoring and ethics committee was not required. All serious adverse events are reported to the sponsor according to current guidelines and the trial steering committee.

### Current status and timescale {#s2i5}

Recruitment started in January 2016 and follow-up of the last participant was completed by end of August 2018.

Discussion {#s3}
==========

Younger adults with T2D are at very high lifetime risk of developing HF. Concentric LV remodelling with associated diastolic dysfunction appears to be the earliest manifestation of diabetic cardiomyopathy. The occurrence of diastolic dysfunction reflects abnormal LV relaxation and increased LV stiffness and has been shown to predict an increased risk of developing overt HF within 5 years.[@R74] Reported prevalence rates of diastolic dysfunction in asymptomatic patients with T2D are as high as 78%.[@R75] Therapies that may reverse diastolic dysfunction or prevent progression to overt chronic HF are therefore urgently needed.

In the DiRECT study delivered in primary care, an MRP programme led to an average weight loss of 10 kg and remission of diabetes in 46% of overweight or obese patients with T2D.[@R27] The cardiovascular benefits of weight loss, however, are less well characterised in T2D, although a reduction in myocardial steatosis and improved diastolic filling has been shown with a VLED in T2D.[@R35] A more substantial body of evidence exists for the beneficial cardiovascular effects of weight loss in obese non-diabetic subjects including: reductions in mass/volume, improved diastolic dysfunction and arterial stiffness.[@R33]

Similarly, exercise training has favourable effects on glycaemic control and cardiovascular outcomes in T2D.[@R38] These benefits of exercise training appear independent of weight loss, suggesting that the underlying mechanisms are different.[@R40] However, data supporting positive effects of exercise training on diastolic dysfunction in T2D are lacking, although reversal of diastolic dysfunction with exercise has been demonstrated in subjects with obesity.[@R44] This study will be among the first to compare and establish the effects of weight loss and exercise on cardiac structure and function in younger adults with T2D. If either of these interventions were to successfully reduce diastolic dysfunction, it is likely that the outcome will contribute to national and international guidelines in this area.

Other interventions that may improve diastolic dysfunction {#s3a}
----------------------------------------------------------

Newer glucose-lowering therapies may improve cardiovascular (CV) outcomes in patients with T2D. Sodium glucose cotransport-2 inhibitors reduce the risk of HF and glucagon-like peptide-1 receptor agonists lower thrombotic events,[@R77] but for optimum benefit, they will require to be used in conjunction with lifestyle interventions, which may actually modify the underlying pathophysiological process of T2D development. Similarly, intensive blood pressure lowering may or may not improve CV outcomes in patients with T2D, but there are inconsistencies in the recommended blood pressure targets.[@R55] Current National Institute for Health and Care Excellence (NG28) recommendations are that blood pressure be maintained below 140/80 mm Hg in uncomplicated T2D or below 130/80 mm Hg if there is a history of kidney, eye or cerebrovascular disease.[@R55] Importantly, both MRP diets[@R31] and exercise[@R80] have favourable effects on blood pressure, supporting these strategies as interventions for CV risk reduction in T2D.

Limitations {#s3b}
-----------

This is a proof-of-efficacy study and therefore effects on clinical outcomes are not planned with a short duration of follow-up. Only patients who are able to exercise and willing to undertake the MRP are eligible, and we have limited our inclusion to younger adults (\<65 years) with a maximum duration of diabetes of 12 years, so the results will not necessarily be generalisable to all people with T2D. The study interventions, given their nature, are not blinded, but ascertainment bias is limited by the blinded assessment of the primary outcome and other imaging parameters. Only the core lab is performing the quantitative analysis of blinded images, and we will not request that another laboratory performs independent segmentation analysis for evaluation of interlaboratory variation. However, a subset of 10 randomly selected CMR datasets was reviewed by an internationally regarded independent expert (Professor Sven Plein, Leeds, UK) to assure data quality and integrity. A smaller-than-expected treatment effect in the intervention arms of the study could render the study underpowered, although the current dropout rate is closer to 20% than the allowed for 30%. The participants in the intervention arms receive increased contact with study investigators that will only partially be offset by health coaching that is administered at baseline to the control group. Follow-up of the last participant recruited to the study was completed by the end of August 2018, which limits changes to data collection.

Declarations {#s3c}
------------

### Ethics and dissemination {#s3c1}

The study is conducted in accordance with the principles of the 1996 Helsinki Declarations, International Conference on Harmonisation-Good Cinical Practice (ICH-GCP) guidelines. It is anticipated that data collection will be completed by end of August 2018, and the study results will be submitted for publication within 6 months of completion.
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